发布求助
文献互助 智能选刊 最新文献

Personalized medicine最新文献

筛选
英文 中文
Clinician perspectives on communication and implementation challenges in precision oncology. 临床医生对精准肿瘤学中沟通和实施挑战的看法。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-22 DOI: 10.2217/pme-2021-0048
Jada G Hamilton, Smita C Banerjee, Sigrid V Carlsson, Jacqueline Vera, Kathleen A Lynch, Lili Sar-Graycar, Chloé M Martin, Patricia A Parker, Jennifer L Hay
{"title":"Clinician perspectives on communication and implementation challenges in precision oncology.","authors":"Jada G Hamilton,&nbsp;Smita C Banerjee,&nbsp;Sigrid V Carlsson,&nbsp;Jacqueline Vera,&nbsp;Kathleen A Lynch,&nbsp;Lili Sar-Graycar,&nbsp;Chloé M Martin,&nbsp;Patricia A Parker,&nbsp;Jennifer L Hay","doi":"10.2217/pme-2021-0048","DOIUrl":"https://doi.org/10.2217/pme-2021-0048","url":null,"abstract":"<p><p><b>Aim:</b> To describe patient communication challenges encountered by oncology clinicians, which represent a fundamental barrier to implementing precision oncology. <b>Materials & methods:</b> We conducted three focus groups including breast, melanoma and thoracic oncology clinicians regarding their precision oncology communication experiences. Transcripts were reviewed and coded using inductive thematic text analysis. <b>Results:</b> We identified four themes: varied definitions of precision oncology exist, clinicians and patients face unique challenges to precision oncology implementation, patient communication challenges engendered or heightened by precision oncology implementation and clinician communication solutions and training needs. <b>Conclusion:</b> This study elucidated clinicians' perspectives on implementing precision oncology and related communication challenges. Understanding these challenges and developing strategies to help clinicians navigate these discussions are critical for ensuring that patients reap the full benefits of precision oncology.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"559-572"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607478/pdf/pme-18-559.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39540497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives. 中欧个体化医疗科技合作:综述、趋势和未来展望。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-06-01 DOI: 10.2217/pme-2021-0030
Ilaria Romagnuolo, Claudia Mariut, Andrea Mazzoni, Giovanni de Santis, Ejner Moltzen, Wolfgang Ballensiefen, Carolin Lange, Andrea Frosini, Gianni D'Errico
{"title":"Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives.","authors":"Ilaria Romagnuolo,&nbsp;Claudia Mariut,&nbsp;Andrea Mazzoni,&nbsp;Giovanni de Santis,&nbsp;Ejner Moltzen,&nbsp;Wolfgang Ballensiefen,&nbsp;Carolin Lange,&nbsp;Andrea Frosini,&nbsp;Gianni D'Errico","doi":"10.2217/pme-2021-0030","DOIUrl":"https://doi.org/10.2217/pme-2021-0030","url":null,"abstract":"<p><p><b>Aim:</b> Personalized medicine (PM) is revolutionizing biomedical and clinical research while improving the ways healthcare is delivered. The EU is at the forefront of science and innovation in this field, increasing collaborations worldwide. This paper aims to assess the status of recent collaborations between Europe and China in PM-related science, technology and funded research. <b>Methods:</b> We analyze scientific literature, patents and funding programs, respectively. <b>Results:</b> PM is a scientific and industrial priority in both geographical areas, but current levels of collaboration are suboptimal. To increase these levels, policy makers should promote cooperation between researchers, innovators, industries, regulators, funding agencies and healthcare systems, while providing a forum to exchange best practices, define common guidelines for PM implementation and promote public-private partnerships.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"455-470"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39038040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. 胰管腺癌的个体化治疗方法及其在外科实践中的应用。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-22 DOI: 10.2217/pme-2021-0031
Dimitrios Schizas, Alkmini Koumpoura, Meropi Galari, Panagiota Economopoulou, Michail Vailas, Maria Sotiropoulou, Dimitrios Dimitroulis, Ioannis Maroulis, Evangelos Felekouras
{"title":"A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice.","authors":"Dimitrios Schizas,&nbsp;Alkmini Koumpoura,&nbsp;Meropi Galari,&nbsp;Panagiota Economopoulou,&nbsp;Michail Vailas,&nbsp;Maria Sotiropoulou,&nbsp;Dimitrios Dimitroulis,&nbsp;Ioannis Maroulis,&nbsp;Evangelos Felekouras","doi":"10.2217/pme-2021-0031","DOIUrl":"https://doi.org/10.2217/pme-2021-0031","url":null,"abstract":"<p><p>Pancreatic duct adenocarcinoma is an aggressive tumor which constitutes the fourth leading cause of cancer-related mortality in the USA. Despite the fact that surgery is an integral part of treatment, 5-year survival rates remain unfavorable, partly because of the complex genetic background, delayed diagnosis and also the absence of effective therapeutic approaches. To optimize surgery's results in recent years, the use of patients' genetic profile has been implemented through classification into subtypes; subtypes based on mutations which could efficiently lead oncologists to the path of targeted novel neoadjuvant regimens. This approach aims to achieve the most effective selection of patients undergoing surgery, to increase the number of potentially resectable tumors and also control micro-metastases, aiming to extend overall survival.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"613-627"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Healthcare professionals' knowledge, attitudes and future expectations towards personalized medicine. 医疗保健专业人员对个性化医疗的知识、态度和未来期望。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-18 DOI: 10.2217/pme-2020-0185
Tayachew Admas, Aklilu Banjaw
{"title":"Healthcare professionals' knowledge, attitudes and future expectations towards personalized medicine.","authors":"Tayachew Admas,&nbsp;Aklilu Banjaw","doi":"10.2217/pme-2020-0185","DOIUrl":"https://doi.org/10.2217/pme-2020-0185","url":null,"abstract":"<p><p><b>Aim:</b> Personalized medicine (PM) is a novel approach to diagnose and treat disease. The study assessed the knowledge, attitudes and future expectations of healthcare professionals (HPs) towards PM in Ethiopia. <b>Materials & methods:</b> A cross-sectional survey with primary data and a simple random sampling technique was applied to collect data. <b>Results:</b> Our study revealed from a total of 384 respondents, 98 (25.5%), 146 (38%) and 140 (36.5%) had good, medium and poor knowledge of PM, respectively. However, 172 (44.8%), 185 (48.2%) and 27 (7%) had positive, neutral and negative attitudes towards PM, respectively. <b>Conclusion:</b> Most respondent's future expectations of PM were positive. Education level had a significant association with attitudes and other sociodemographic variables were not significant for both knowledge and attitude.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"483-490"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A GRIN3A polymorphism may be associated with glucocorticoid-induced symptomatic osteonecrosis in children with acute lymphoblastic leukemia. GRIN3A多态性可能与急性淋巴细胞白血病儿童糖皮质激素诱导的症状性骨坏死有关。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-18 DOI: 10.2217/pme-2020-0167
Nathalie K Zgheib, Habib El-Khoury, Dimitri Maamari, Maya Basbous, Raya Saab, Samar A Muwakkit
{"title":"A <i>GRIN3A</i> polymorphism may be associated with glucocorticoid-induced symptomatic osteonecrosis in children with acute lymphoblastic leukemia.","authors":"Nathalie K Zgheib,&nbsp;Habib El-Khoury,&nbsp;Dimitri Maamari,&nbsp;Maya Basbous,&nbsp;Raya Saab,&nbsp;Samar A Muwakkit","doi":"10.2217/pme-2020-0167","DOIUrl":"https://doi.org/10.2217/pme-2020-0167","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the association between candidate genetic polymorphisms and glucocorticoid-induced osteonecrosis in Arab children treated for acute lymphoblastic leukemia. <b>Methods:</b> A total of 189 children treated for acute lymphoblastic leukemia were genotyped for four SNPs with allele discrimination assays. The incidence and timing of radiologically confirmed symptomatic grade 4 osteonecrosis were classified based on the Ponte di Legno toxicity working group consensus definition. <b>Results:</b> Thirteen children developed grade 4 osteonecrosis (6.8%), of whom 12 received the intermediate/high-risk treatment protocol. <i>GRIN3A</i> variant allele carriers had to stop dexamethasone therapy earlier resulting in significantly shorter duration of dexamethasone treatment (mean [95% CI]: 75.17 [64.28-86.06] vs 85.90 [81.22-90.58] weeks; p = 0.054) and lower cumulative dose (mean [95% CI]: 1118.11 [954.94-1281.29] vs 1341.14 [1264.17-1418.11] mg/m<sup>2;</sup> p = 0.011). <b>Conclusion:</b> This is the first pharmacogenomics evaluation of the association between <i>GRIN3A</i> variants and glucocorticoid-induced osteonecrosis in Arab children.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"431-439"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
After decades, RAS mutation has finally become a therapeutic target. 几十年后，RAS突变终于成为治疗靶点。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-18 DOI: 10.2217/pme-2021-0015
Nabih Naim, Sara Moukheiber, Karim Jaber, Hampig Raphael Kourie
{"title":"After decades, RAS mutation has finally become a therapeutic target.","authors":"Nabih Naim,&nbsp;Sara Moukheiber,&nbsp;Karim Jaber,&nbsp;Hampig Raphael Kourie","doi":"10.2217/pme-2021-0015","DOIUrl":"https://doi.org/10.2217/pme-2021-0015","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"523-525"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39524337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of protective haplotypes of the SLCO1B1 gene for statin transport in Mexican populations. SLCO1B1基因他汀类转运保护性单倍型在墨西哥人群中的患病率。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-22 DOI: 10.2217/pme-2020-0172
Alma Faviola Favela-Mendoza, Brenda Guadalupe Rodríguez-Rodríguez, Eduardo Rojas-Prado, Mariana Chávez-Arreguin, José Alonso Aguilar-Velázquez, Gabriela Martínez-Cortés, Héctor Rangel-Villalobos
{"title":"Prevalence of protective haplotypes of the <i>SLCO1B1</i> gene for statin transport in Mexican populations.","authors":"Alma Faviola Favela-Mendoza,&nbsp;Brenda Guadalupe Rodríguez-Rodríguez,&nbsp;Eduardo Rojas-Prado,&nbsp;Mariana Chávez-Arreguin,&nbsp;José Alonso Aguilar-Velázquez,&nbsp;Gabriela Martínez-Cortés,&nbsp;Héctor Rangel-Villalobos","doi":"10.2217/pme-2020-0172","DOIUrl":"https://doi.org/10.2217/pme-2020-0172","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the genetic distribution of the <i>rs4149056</i> and <i>rs2306283</i> variants in the <i>SLCO1B1</i> gene in Mexican Mestizo (admixed) and Native American groups. <b>Materials & methods:</b> We recruited 360 volunteers who were qPCR-genotyped with TaqMan probes. <b>Results:</b> Allele and genotype frequencies are reported. Among the expected <i>rs4149056</i>-<i>rs2306283</i> haplotypes, T-A (42.35-58.47%) was the most prevalent which relates to the normal activity of the OATP1B1 transporter. This was followed by the T-G haplotype associated with further statin transport and cholesterol reduction (32.49-43.76%). <b>Conclusion:</b> Based on these <i>SLCO1B1</i> gene variants, we confirmed that a minimum fraction of the Mexican study populations would be at risk from decreasing simvastatin transport and the development of statin-induced myopathy.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"533-540"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39540499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of serum miR-101-3p expression in patients with neonatal sepsis. 新生儿脓毒症患者血清miR-101-3p表达的临床意义
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-06 DOI: 10.2217/pme-2020-0182
Juan Zhang, Xinwei Xu, Min Wang
{"title":"Clinical significance of serum <i>miR-101-3p</i> expression in patients with neonatal sepsis.","authors":"Juan Zhang,&nbsp;Xinwei Xu,&nbsp;Min Wang","doi":"10.2217/pme-2020-0182","DOIUrl":"https://doi.org/10.2217/pme-2020-0182","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to evaluate the levels and functions of <i>miR-101-3p</i> in neonatal sepsis (NS). <b>Materials & methods:</b> Quantitative real-time PCR was conducted to investigate the expression of <i>miR-101-3p</i> and the receiver operating characteristic curve was applied to manifest its diagnostic effects. <b>Results:</b><i>miR-101-3p</i> was increased in the NS patients and the dysregulation of <i>miR-101-3p</i> was associated with levels of procalcitonin, CRP, IL-8 and TNF-α. The combination of <i>miR-101-3p</i> and procalcitonin could function as a promising indicator in distinguishing NS patients. The silenced <i>miR-101-3p</i> reversed the increased levels of TNF-α and IL-8 caused by lipopolysaccharide <i>in vitro</i>. <i>DUSP1</i> was identified as a direct target gene of <i>miR-101-3p</i> in NS. <b>Conclusion:</b> The abundance of <i>miR-101-3p</i> facilitated the inflammation in NS by targeting <i>DUSP1</i>.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"541-550"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39486847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Personalized therapy: can it tame the COVID-19 monster? 个性化疗法：它能驯服 COVID-19 怪兽吗？
IF 1.7 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-15 DOI: 10.2217/pme-2021-0077
Mohd Arish, Farha Naz
{"title":"Personalized therapy: can it tame the COVID-19 monster?","authors":"Mohd Arish, Farha Naz","doi":"10.2217/pme-2021-0077","DOIUrl":"10.2217/pme-2021-0077","url":null,"abstract":"<p><p>SARS-CoV-2, a recently emerged zoonotic virus, has resulted in unstoppable high morbidity and mortality rates worldwide. However, due to a limited knowledge of the dynamics of the SARS-CoV-2 infection, it has been observed that the current COVID-19 therapy has led to some clinical repercussions. We discuss the adverse effects of drugs for COVID-19 primarily based on some clinical trials. As therapeutic efficacy and toxicity of therapy may vary due to different, genetic determinants, sex, age and the ethnic background of test subjects, hence biomarker-based personalized therapy could be more appropriate. We will share our thoughts on the current landscape of personalized therapy as a roadmap to fight against SARS-CoV-2 or another emerging pathogen.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"583-593"},"PeriodicalIF":1.7,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39517746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of miR-101 in esophageal and gastric cancer. miR-101在食管癌和胃癌中的作用。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-17 DOI: 10.2217/pme-2021-0024
Athanasios Syllaios, Stratigoula Sakellariou, Nikolaos Garmpis, Eleni Sarlani, Christos Damaskos, Konstantinos Apostolou, Stylianos Kykalos, Maria Gazouli, Ioannis Karavokyros, Dimitrios Schizas
{"title":"The role of miR-101 in esophageal and gastric cancer.","authors":"Athanasios Syllaios,&nbsp;Stratigoula Sakellariou,&nbsp;Nikolaos Garmpis,&nbsp;Eleni Sarlani,&nbsp;Christos Damaskos,&nbsp;Konstantinos Apostolou,&nbsp;Stylianos Kykalos,&nbsp;Maria Gazouli,&nbsp;Ioannis Karavokyros,&nbsp;Dimitrios Schizas","doi":"10.2217/pme-2021-0024","DOIUrl":"https://doi.org/10.2217/pme-2021-0024","url":null,"abstract":"<p><p>miR-101 is downregulated in various types of cancer, leading to the notion that miR-101 acts as a suppressor in cancer cell progression. The comprehensive mechanisms underlying the effects of miR-101 and the exact role of miR-101 dysregulations in esophagogastric tumors have not been fully elucidated. This review aims to summarize all current knowledge on the association between miR-101 expression and esophagogastric malignancies and to clarify the pathogenetic pathways and the possible prognostic and therapeutic role of miR-101 in those cancer types. miR-101 seems to play crucial role in esophageal and gastric cancer biology and tumorigenesis. It could also be a promising novel diagnostic and therapeutic target, as well as it may serve as a significant predictive biomarker in esophagogastric cancer.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"491-499"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39318825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信